Standard BioTools Reports Exit/Disposal Costs
Ticker: LAB · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1162194
| Field | Detail |
|---|---|
| Company | Standard Biotools Inc. (LAB) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $3.6 m, $0.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, 8-K
TL;DR
Standard BioTools is shedding some costs, but details are scarce.
AI Summary
Standard BioTools Inc. filed an 8-K on August 28, 2025, reporting costs associated with exit or disposal activities. The filing does not specify the exact nature or amount of these costs, but it indicates a formal event requiring disclosure under SEC regulations.
Why It Matters
This filing signals potential restructuring or divestiture activities within Standard BioTools, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details regarding the exit or disposal activities creates uncertainty about the financial implications for Standard BioTools.
Key Players & Entities
- Standard BioTools Inc. (company) — Registrant
- August 28, 2025 (date) — Date of earliest event reported
- 2 Tower Place, Suite 2000 (location) — Principal executive offices address
- South San Francisco, California 94080 (location) — Principal executive offices address
- 650-266-6000 (phone_number) — Registrant's telephone number
FAQ
What specific activities are associated with the exit or disposal costs reported by Standard BioTools?
The filing does not specify the exact nature of the exit or disposal activities.
What is the total dollar amount of the costs associated with exit or disposal activities?
The filing does not disclose a specific dollar amount for these costs.
When did the event triggering these costs occur?
The earliest event reported occurred on August 28, 2025.
What is the primary business of Standard BioTools Inc.?
Standard BioTools Inc. is in the business of Laboratory Analytical Instruments (SIC code 3826).
What was the former name of Standard BioTools Inc.?
The former name was Fluidigm Corp, with a date of name change on November 13, 2001.
Filing Stats: 737 words · 3 min read · ~2 pages · Grade level 13.6 · Accepted 2025-09-03 06:05:29
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob
- $3.6 m — and related costs, to be approximately $3.6 million, which includes approximately $0.
- $0.9 million — 6 million, which includes approximately $0.9 million of non-cash expenses related to vesting
Filing Documents
- lab-20250828.htm (8-K) — 48KB
- 0000950170-25-112662.txt ( ) — 190KB
- lab-20250828.xsd (EX-101.SCH) — 51KB
- lab-20250828_htm.xml (XML) — 5KB
05. Costs Associated with Exit or Disposal Activities
Item 2.05. Costs Associated with Exit or Disposal Activities On August 28, 2025, Standard BioTools Inc. (the "Company") determined to consolidate its South San Francisco-based R&D capabilities into its Singapore facility to co-locate with its manufacturing operations and to implement a reduction-in-force of certain U.S. employees in the Company's R&D function, including members of its management team. This is part of a plan to restructure the Company's operating expenses to improve operational efficiency and reduce operating costs, while supporting the execution of the Company's long-term strategic plan. The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $3.6 million, which includes approximately $0.9 million of non-cash expenses related to vesting of share-based awards. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the operational restructuring plan, including the reduction-in-force. The Company expects these costs to be payable over the next several months. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs and timing of costs associated with the reduction-in-force and expected reductions of operating expenses. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which